Multiple Myeloma
Conditions
Brief summary
The myeloma microenvironment is the target of many drugs in development, and it is unclear how they can be combined with reference treatments such as lenalidomide. This pilot study consists of an extensive phenotypic characterisation of the impact of lenalidomide combined with dexamethasone on the bone marrow microenvironment of a homogeneous cohort of non-pretreated MM patients. Blood sampling will be systematically performed in a matched fashion to monitor the general effect of lenalidomide on the immune system and to detect possible peripheral markers. This study will provide rational guidance for future combination therapies with lenalidomide.
Detailed description
With the significant increase in the number of therapeutic combinations targeting the tumour microenvironment, it is crucial to better understand the effect of reference myeloma treatments on the different immune populations present in the tumour in order to rationally optimise the combination with new strategies under development. In addition, the identification of biomarkers in the circulating blood that can predict/monitor the impact of new therapies on the immune response is a major challenge. This pilot study consists of an extensive phenotypic characterisation of the impact of lenalidomide combined with dexamethasone on the bone marrow microenvironment of a homogeneous cohort of non-pretreated MM patients. Blood sampling will be systematically performed in a matched fashion to monitor the general effect of lenalidomide on the immune system and to detect possible peripheral markers.
Interventions
Blood and bone marrow sampling
Sponsors
Rennes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with newly diagnosed multiple myeloma; * Patient not eligible for intensive treatment; * Patient for whom first-line treatment with Lenalidomide-Dexamethasone will be initiated; * Patient accepting the performance of an additional myelogram at the end of the 1st treatment cycle. * Patient aged 18 years or older; * Patient who has given free, informed and written consent; * Patient affiliated to a social security scheme * For women of childbearing age, use of effective contraception
Exclusion criteria
* Patient with relapsed multiple myeloma; * Patient eligible for intensive treatment; * Patient for whom chemotherapy involves treatment other than Lenalidomide-Dexamethasone; * Patient with a contraindication to lenalidomide treatment * Pregnant or breastfeeding woman; * Person subject to legal protection (safeguard of justice, curatorship,guardianship) or person deprived of liberty.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of HLA-DR on medullary T-lymphocytes | 1 month | Changed expression of HLA-DR on medullary T-lymphocytes after exposure to lenalidomide-dexamethasone. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Activation status of biological markers | 1 month | Presence of active protein markers and immune checkpoints by medullary immune cell subpopulations. |
Countries
France
Outcome results
None listed